Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)

PURPOSE: Pre-clinical data indicate that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers. EXPERIMENTAL DESIGN: SPIRE comprised a dose escalation phase for incurable metastatic solid cancers, followed by a randomised dose expansion phase for neoadjuvant treatm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Crabb, Simon J., Danson, Sarah, Catto, James W.F., Hussain, Syed, Chan, Danna, Dunkley, Denise, Downs, Nichola, Marwood, Ellice, Day, Laura, Saunders, Geoff, Light, Michelle, Whitehead, Amy, Ellis, Deborah, Sarwar, Naveed, Enting, Deborah, Birtle, Alison, Johnson, Bernadette, Huddart, Robert, Griffiths, Gareth
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611191/
https://ncbi.nlm.nih.gov/pubmed/33472913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3946
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados